Wasatch Advisors’s Exagen XGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-42,975
Closed -$176K 249
2024
Q4
$176K Sell
42,975
-447,230
-91% -$1.61M ﹤0.01% 232
2024
Q3
$1.51M Sell
490,205
-272,054
-36% -$705K 0.01% 229
2024
Q2
$1.39M Sell
762,259
-24,636
-3% -$41.7K 0.01% 227
2024
Q1
$1.25M Sell
786,895
-63,413
-7% -$123K 0.01% 236
2023
Q4
$1.69M Sell
850,308
-5,965
-0.7% -$10.3K 0.01% 228
2023
Q3
$2.1M Sell
856,273
-144,571
-14% -$367K 0.01% 236
2023
Q2
$2.9M Buy
1,000,844
+283
+0% +$805 0.02% 231
2023
Q1
$2.43M Hold
1,000,561
0.02% 233
2022
Q4
$2.4M Sell
1,000,561
-10,291
-1% -$26.4K 0.02% 232
2022
Q3
$2.74M Sell
1,010,852
-1,093
-0.1% -$6.1K 0.02% 221
2022
Q2
$5.81M Sell
1,011,945
-77,367
-7% -$450K 0.04% 200
2022
Q1
$8.75M Sell
1,089,312
-16,448
-1% -$142K 0.04% 194
2021
Q4
$12.9M Buy
1,105,760
+7,502
+0.7% +$87.9K 0.05% 190
2021
Q3
$14.9M Sell
1,098,258
-595,420
-35% -$7.92M 0.06% 187
2021
Q2
$25.4M Buy
1,693,678
+2,171
+0.1% +$33.3K 0.1% 165
2021
Q1
$29.6M Buy
1,691,507
+647,104
+62% +$11.5M 0.13% 134
2020
Q4
$13.8M Buy
1,044,403
+100,572
+11% +$1.42M 0.07% 175
2020
Q3
$10.2M Buy
943,831
+325,786
+53% +$4.2M 0.07% 174
2020
Q2
$7.67M Sell
618,045
-74,374
-11% -$1.01M 0.06% 173
2020
Q1
$11M Buy
692,419
+341,006
+97% +$6.77M 0.11% 126
2019
Q4
$8.93M Sell
351,413
-19,415
-5% -$345K 0.07% 161
2019
Q3
$5.74M Buy
+370,828
New +$5.99M 0.05% 172

Other funds holding XGN

Wasatch Advisors's XGN Position: Q1 2025 in Review

Wasatch Advisors sold out of Exagen (XGN) in Q1 2025, closing a stake of 42,975 shares — an estimated $176K sold.

Wasatch Advisors first reported a position in XGN in Q3 2019 and held it in 22 quarters. The position peaked at $29.6M in Q1 2021. 38 funds tracked by Wall St. Rank hold XGN as of Q1 2025.

  • Wasatch Advisors reported no remaining Exagen position as of Q1 2025 after selling out during the quarter.
  • Wasatch Advisors sold 42,975 Exagen shares in Q1 2025, an estimated $176K.
  • Wasatch Advisors first reported a position in Exagen in Q3 2019 and held it in 22 quarters.
  • Wasatch Advisors's Exagen position peaked at $29.6M in Q1 2021.
  • 38 funds tracked by Wall St. Rank held Exagen as of Q1 2025.

Based on Wasatch Advisors's 13F filing for Q1 2025, filed 15 May 2025.